Small-Cap Breakout: The Countdown to Catalysts Begins (MBOT, NLSP, SVRE, NITO, AZTR)

Every week, we explore emerging market opportunities, seeking small-cap stocks poised for explosive growth. Our spotlight is on five exceptional picks, selected using key signals like resistance breakouts, sharp volume increases, and strong consolidation trends.

Microbot Medical, Inc. (NASDAQ: MBOT) - Microbot Medical, Inc. shares closed last week up 11% at $1.11, accompanied by unusually high trading volume for the month. In October, the company announced the successful completion of patient enrollment and follow-up for its ACCESS-PVI human clinical trial. Microbot remains on track to file its 510(k) submission with the FDA by the end of 2024, having officially submitted it on December 10, 2024. “We are very pleased with the performance of LIBERTY® throughout the study,” stated Dr. Juan Diaz-Cartelle, Chief Medical Officer. “We extend our gratitude to the investigators for their commitment to the trial. We plan to share the clinical trial results with the medical community and the public at a conference in early 2025.” Harel Gadot, Chairman, CEO, and President of Microbot, called this milestone a "monumental moment and significant achievement," adding that physician feedback has been highly encouraging. The company is simultaneously preparing its go-to-market strategy and building a commercial infrastructure to support the anticipated launch of LIBERTY® upon FDA clearance, expected in Q2 2025. Gadot also emphasized LIBERTY®'s transformative potential: "We are excited to shift our focus toward preparing for our expected U.S. launch in the second quarter of 2025 and targeting the more than 2 million peripheral vascular procedures performed annually in the U.S. Feedback from physicians and the medical community reinforces our belief that LIBERTY® is poised to redefine the peripheral endovascular space with the world’s first commercially available single-use robotic system." As the first fully disposable, single-use endovascular robotic system, LIBERTY® eliminates the need for costly capital equipment, improves accessibility to robotics, and is remotely controlled to reduce radiation exposure and physical strain on healthcare providers. The system is also expected to lower procedure costs, enhance efficiency, and improve overall care quality. We will be closely monitoring for a resistance break at $1.20, accompanied by sustained increases in trading volume, as we await further updates from the company.

--

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) - NLS Pharmaceutics Ltd. shares closed last week at $1.82, marking a 2% decline. This month, the company released a shareholder letter from CEO Alex Zwyer, detailing recent achievements, challenges, and future opportunities as they approach the expected closing of a transformative merger with Kadimastem Ltd., an advanced clinical-stage company. Over the past several months, NLS has made significant progress with its Dual Orexin Receptor Agonist (DOXA) platform, which shows promise in addressing challenges related to sleep and neurodegenerative disorders. The company is currently evaluating two candidates, AEX-41 and AEX-2, as first-in-class non-sulfonamide DOXAs that target orexin-1 and orexin-2 receptors while inhibiting cathepsins, a novel approach to meeting unmet needs in narcolepsy and related neurological conditions. Preliminary results from a study on AEX-41 in narcolepsy models, shared earlier this month, indicate its potential as a treatment for sleep-wake disturbances, with final top-line results expected by year-end. Additionally, the company plans to expand its DOXAplatform to explore applications in other neurodegenerative diseases, including ALS. On the financial front, NLS has successfully eliminated all debt and strengthened its balance sheet. In October 2024, the company raised $3.2 million in a private placement, followed by a second private placement in December for up to $1 million at a 15% premium to market value, pending shareholder approval. These efforts, combined with the company’s existing cash position, have extended its financial runway to approximately 18 months, providing the flexibility to advance DOXA development and finalize the merger process. The merger with Kadimastem is expected to close by the end of January 2025. Kadimastem’s expertise in innovative cell-based therapies is expected to enhance the DOXAprogram and integrate it into the merged company’s broader pipeline, which includes treatments for neurodegenerative conditions and diabetes. NLS has described this merger as a significant strategic opportunity, offering benefits not only for the company but also for shareholders. The combined entity plans to maximize shareholder value through the potential sale of legacy assets tied to a contingent value right (CVR) and through a stronger, more focused clinical pipeline. We will be watching closely for a resistance break at $1.90–$1.95, supported by increased trading volume, as we await further updates from the company.

--

SaverOne 2014 Ltd. (NASDAQ: SVRE) - SaverOne 2014 Ltd. ended last week’s trading session up nearly 5%, closing at $1.10. This month, the company announced a significant pilot project with Trans Italia, a leading Italian logistics and transportation firm known for its eco-friendly and efficient intermodal solutions. This pilot represents a key milestone in SaverOne’s expansion into the Italian market and its broader European growth plans. The initiative involves installing SaverOne’s innovative driver safety system in a selection of Trans Italia’s trucks, showcasing its ability to prevent driver distractions and improve road safety. With a fleet of over 300 trucks, Trans Italia presents a substantial growth opportunity and serves as a strategic platform to demonstrate SaverOne’s technology to the Italian logistics and eco-friendly transportation sectors. Additionally, SaverOne announced a new distribution agreement with Smartfits Installations Ltd., a UK-based fleet safety and technology integration company. This partnership aims to bring SaverOne’s distraction prevention technology to fleets across the United Kingdom, spanning industries such as logistics, public transport, and corporate fleets. In Israel, the company also expanded its deployment within another division of a global food manufacturer’s subsidiary, adding its systems to a fleet of employee vehicles following a successful earlier implementation in trucks and other vehicles. In a recent filing, SaverOne shared updates on its OEM solution, which aims to integrate its driver distraction prevention technology directly into the vehicle manufacturing process. This solution, developed in collaboration with a leading global OEM, is in its early stages, with a planned launch in the first half of 2025. While development costs remain uncertain, this advancement underscores the company’s long-term strategy to embed its technology at the core of vehicle production. We will be monitoring for a resistance break at $1.20, accompanied by increased trading volume, as we await additional updates from the company.

--

N2OFF, Inc (NASDAQ: NITO) - N2OFF, Inc. shares closed last week’s trading session down nearly 5%, ending at $0.24. In October, the company announced key strategic initiatives approved by its board of directors aimed at increasing shareholder value. One major initiative is the potential spin-off of its cleantech operations—NTWO OFF Ltd. and Save Foods Ltd.—into a separate publicly traded company, with plans to list the new entity on a national exchange. Following the spin-off, N2OFF intends to maintain a controlling stake of at least 75% in Save Foods Ltd. and will appoint all members of the new entity's board of directors. The timing and terms of any dividends or distributions related to the new entity will be determined by its board at their discretion. Additionally, N2OFF has entered into a non-binding letter of intent (LOI) to acquire a drug discovery company specializing in advanced computational structural biology. The acquisition, which is valued at a minimum of $5 million with potential for an additional $2 million in valuation, is expected to be financed through a combination of cash and equity. N2OFF believes this acquisition will allow it to enter a new and lucrative market, expanding the drug discovery company's reach into advanced pharmaceutical research. CEODavid Palach expressed pride in leading a company driven by a strong team and a forward-thinking board, emphasizing that these strategic decisions should enhance the company’s position in the cleantech and pharmaceutical sectors while delivering long-term value to shareholders. This month, the company also filed a loan agreement with MitoCareX Bio Ltd., an Israeli private company, and L.I.A. Pure Capital Ltd., another Israeli company. Under the agreement, N2OFF will loan $250,000 to MitoCareX, with interest accruing at an annual rate tied to USD exchange rate fluctuations, plus 3%. The loan has a six-month term, with the principal and accrued interest due at maturity. If MitoCareX becomes a subsidiary of the company, any outstanding loan balance will be deducted from future allocations to MitoCareX during the first year after the transaction. Pure Capital has guaranteed the repayment of the loan by MitoCareX. As we await further updates, we will be closely watching for a resistance break in the $0.28–$0.29 range, supported by increased trading volume.

--

Azitra Inc. (NYSE: AZTR) - Azitra Inc. shares ended last week’s trading session up 14%, closing at $0.46. Last month, the company reported its financial results for the three months ending September 30, 2024, and provided a business update. CEO Francisco Salva highlighted key achievements, including dosing the first patient with ATR-12 in the ongoing Netherton syndrome trial. During the same period, the company completed a follow-on offering, raising $10 million in gross proceeds, submitted an IND for ATR-04 for skin rash caused by epidermal growth factor receptor inhibitors (EGFRis), received IND clearance and Fast Track designation for ATR-04, and strengthened its intellectual property portfolio. Salva emphasized that with a clear roadmap, strong execution on two programs, and a dedicated team, Azitra is well-positioned to achieve its milestones, deliver transformative therapies to patients, and maximize shareholder value. Looking ahead, Azitra expects key milestones in Q1 2025, including the release of initial safety data from the first set of Netherton syndrome patients in the Phase 1b trial and the dosing of the first patient with ATR-04 for EGFRi rash in a Phase 1/2 trial. This month, the company also announced its participation in Biotech Showcase 2025, which will be held January 13-15, 2025, in San Francisco. During the conference, Azitra’s management team will conduct one-on-one meetings with registered investors and potential partners to showcase the company’s business and clinical development strategy, recent achievements, and anticipated milestones. As we await further updates from the company, we will be watching for increased trading volume and a potential resistance break in the $0.48–$0.49 range.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. We have been compensated one thousand dollars via a third party (Mt Zion Market Ventures LLC) for 15 days (12/26/24-1/9/25) of advertising, marketing, and social media services on SaverOne 2014 Ltd. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.